Ablynx CEO: fundraising lets us take on more risk and responsibility
This article was originally published in Scrip
With the €50 million Ablynx has just raised, the Belgian antibody firm has extended its ability to take on more risks in return for greater potential rewards, and to progress its internal programmes, CEO Dr Edwin Moses told Scrip, the day after closing the secondary public offering. "Even without it we had well over two years in funding available," he noted, "but this gives us flexibility and choice."
You may also be interested in...
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.